These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. [Apropos of corticoid therapy of acute viral hepatitis at the early phase]. Laverdant C; Molinié C; Essioux H; Daly JP Gastroenterol Clin Biol; 1978; 2(6-7):652-3. PubMed ID: 680487 [No Abstract] [Full Text] [Related]
45. Interferon signalling through arachidonic acid-dependent pathways: a clue to adjuvant therapy for chronic viral hepatitis? Baskin G Hepatology; 1991 Aug; 14(2):392-4. PubMed ID: 1713568 [No Abstract] [Full Text] [Related]
46. Levamisole in viral hepatitis. Pár A; Barna K; Hollós I; Kovács M; Miszlai Z; Patakfalvi A; Javor T Lancet; 1977 Mar; 1(8013):702. PubMed ID: 66499 [No Abstract] [Full Text] [Related]
47. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. Gentile I; Borgia G J Hepatol; 2010 May; 52(5):778. PubMed ID: 20347500 [No Abstract] [Full Text] [Related]
48. [Acute viral hepatitis. Its treatment with cytosine arabinoside]. de la Torre Fernandez JM; Montero Vázquez J; Capote Armas LF; Domínguez Carmona A Rev Esp Enferm Apar Dig; 1977 Mar; 49(5):607-20. PubMed ID: 323938 [No Abstract] [Full Text] [Related]
49. [The treatment of acute viral hepatitis with (+)-cyanidanol-3]. Pelloni S; Berthet P; Blum AL; Doelle W; Goebell H; Kortüm K; Peter P; Poulsen H; Strohmeyer G; Tygstrup N Schweiz Med Wochenschr; 1977 Dec; 107(49):1859-61. PubMed ID: 337476 [No Abstract] [Full Text] [Related]
50. [Efficacy of glucocorticoid on the early stage of severe viral hepatitis]. Gu CH; He CQ; Wang GX Zhonghua Nei Ke Za Zhi; 1988 Aug; 27(8):480-2, 518. PubMed ID: 3219955 [No Abstract] [Full Text] [Related]
51. [Viral hepatitis (type B, type C, type D)]. Kiyosawa K Nihon Rinsho; 2007 Mar; 65 Suppl 3():241-6. PubMed ID: 17494151 [No Abstract] [Full Text] [Related]
52. Therapy of chronic viral hepatitis: past, present, and future. Hoofnagle JH; Jones EA Semin Liver Dis; 1989 Nov; 9(4):231-4. PubMed ID: 2690347 [No Abstract] [Full Text] [Related]
54. The therapeutic effect of biphenyl-dimethyl-dicarboxylate (DDB) on certain abnormal laboratory parameters in chronic hepatitis. Zhang YX; Yu HQ; Shi JZ; Qi HB; Dong ZH; Xu HY J Tradit Chin Med; 1987 Jun; 7(2):137-8. PubMed ID: 3448395 [No Abstract] [Full Text] [Related]
55. Management of chronic hepatitis. Part two: treatment. Mistilis SP; Lam KC Med J Aust; 1980 Mar; 1(6):256-60. PubMed ID: 6154882 [No Abstract] [Full Text] [Related]
56. [Effect of ampevit hydrolysate on the pigment metabolism and antitoxic function of the liver in viral hepatitis]. Artiushchenko II Pediatr Akus Ginekol; 1977 Dec; (6):24-5. PubMed ID: 343051 [No Abstract] [Full Text] [Related]
57. International Journal of Antimicrobial Agents Themed Section Issue: "Therapeutics of hepatitis viruses". Colson P; Capobianchi MR Int J Antimicrob Agents; 2020 Jul; 56(1):105402. PubMed ID: 29574016 [No Abstract] [Full Text] [Related]
58. Increase in triglycerides during alpha-interferon treatment of chronic viral hepatitis. Ruiz-Moreno M; Carreño V; Rúa MJ; Cotonat T; Serrano B; Santos M; Marriott E J Hepatol; 1992 Nov; 16(3):384. PubMed ID: 1487617 [No Abstract] [Full Text] [Related]
59. Chronic viral hepatitis. From clinical trials to the therapeutic decision in the individual patient. Bonino F J Hepatol; 1991; 13 Suppl 1():S27-30. PubMed ID: 1960377 [No Abstract] [Full Text] [Related]
60. [Critique on the drug treatment of chronic viral hepatitis (author's transl)]. Dai ZY Zhonghua Nei Ke Za Zhi; 1979; 18(3):161-2. PubMed ID: 555907 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]